Aclaris Therapeutics Inc Stock Price, News & Analysis

Aclaris Therapeutics (NASDAQ:ACRS) announced that additional data from its Phase 2a trial of ATI-2138 in atopic dermatitis will be presented as a late-breaking abstract at the 2025 EADV Congress in Paris. ATI-2138 is a selective oral covalent inhibitor targeting ITK and JAK3 for moderate-to-severe atopic dermatitis treatment.

The presentation, titled "Molecular and Clinical Effects of oral ATI-2138," will be delivered by Dr. Jessica Beaziz-Tordjman on September 18, 2025, at 14:15 CEST. The study's results will provide insights into the drug's effectiveness in treating moderate-to-severe atopic dermatitis patients.

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, has announced its participation in two major healthcare conferences in September 2025.

CEO Dr. Neal Walker and the senior leadership team will participate in a fireside chat at the Cantor Global Healthcare Conference on September 3 at 1:00 PM EDT. Additionally, Dr. Walker will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 9:00 AM EDT. Both events will be webcast live and archived on the company's website.

Aclaris Therapeutics (NASDAQ:ACRS) reported Q2 2025 financial results and provided significant pipeline updates. The company achieved positive results in its Phase 2a trial of ATI-2138, their ITK/JAK3 inhibitor for atopic dermatitis, demonstrating strong efficacy and tolerability. Additionally, Aclaris initiated dosing in two key trials: a Phase 2 trial of bosakitug (anti-TSLP antibody) and a Phase 1a/1b program for ATI-052 (anti-TSLP/IL-4R bispecific antibody).

Financially, Aclaris reported a net loss of $15.4 million in Q2 2025, with cash reserves of $180.9 million as of June 30, 2025. The company expects its current cash position to fund operations into the second half of 2028. R&D expenses increased to $11.4 million, primarily due to expanded clinical development activities.

Aclaris Therapeutics (NASDAQ: ACRS) announced positive top-line results from its Phase 2a trial of ATI-2138, an oral inhibitor targeting ITK and JAK3, for atopic dermatitis treatment. The trial met its primary endpoint, demonstrating a favorable safety profile with no severe adverse events.

Key efficacy results showed a 60.5% mean improvement in EASI score at week 12, reaching 77.1% when excluding one outlier patient. Additionally, 62.5% of patients achieved significant itch reduction. The drug demonstrated strong pharmacodynamic results, with 90% ITK target occupancy at peak and significant downregulation of inflammatory markers.

Based on these results, Aclaris plans to advance ATI-2138's development for alopecia areata and explore additional indications. The company is also developing next-generation ITK inhibitors, with new INDs expected in 2026.

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, has announced a significant leadership transition in its scientific team. Roland Kolbeck, Ph.D. has been appointed as the new Chief Scientific Officer, succeeding Joe Monahan, Ph.D., who will transition to a Special Scientific Advisor role through Q1 2026 as part of his planned retirement.

Dr. Kolbeck brings nearly 30 years of senior R&D leadership experience, most recently serving as CSO at Spirovant Sciences. His notable achievements include his role as VP and Head of Respiratory, Inflammation and Autoimmune Research at MedImmune, where six monoclonal antibodies from his portfolio received FDA approval. The transition comes as Aclaris continues to develop its portfolio of immuno-inflammatory product candidates, including next-generation kinase inhibitors and first-in-class bispecific antibodies.

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has been added to both the Russell 2000® and Russell 3000® Indexes following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.

The inclusion comes as part of FTSE Russell's annual reconstitution process, which ranks the 4,000 largest US stocks by market capitalization. Notably, approximately $10.6 trillion in assets are benchmarked against Russell US indexes as of June 2024. Membership in these indexes will remain in place for one year.

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, will deliver a corporate presentation at the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation is scheduled for Monday, June 30, 2025 at 11:30 AM EDT.

Investors and interested parties can access both the live and archived versions of the presentation through the Events page on the company's website, where it will remain available for a minimum of 30 days.

Aclaris Therapeutics (NASDAQ: ACRS) has initiated a Phase 1a/1b program for ATI-052, a novel bispecific antibody targeting both TSLP and IL-4R for immuno-inflammatory diseases. The program includes a Phase 1a single and multiple ascending dose study in healthy volunteers, followed by a Phase 1b proof of concept portion. ATI-052 is designed with high binding affinity to dual-block both upstream and downstream targets in Th2-mediated inflammation and allergic diseases. The Phase 1a portion will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ATI-052. Phase 1a results are expected by year-end 2025 with top-line results in early 2026, while Phase 1b results are anticipated in H2 2026.

Aclaris Therapeutics (NASDAQ: ACRS) has initiated a Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis. The trial follows successful Phase 2a results where bosakitug showed impressive efficacy with 94% of participants achieving EASI-75 scores and 88% achieving clear or nearly clear skin (IGA 0/1) at week 26. The new randomized, double-blind, placebo-controlled global study will evaluate approximately 90 patients, with primary endpoint measuring EASI score changes at week 24. Bosakitug, positioned as a potential best-in-class anti-TSLP therapeutic monoclonal antibody, demonstrates superior potency, residence time, and unique TSLP binding characteristics. Top-line results are expected in the second half of 2026.